Clinical trial

Anti-IgE Monoclonal Antibody Treatment in Patients With Allergic Asthma.

NCT03468790

Drugs and interventions used in this trial

5 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention CMAB007 Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Symbicort Normalized identity: SymbicortView linked drug · Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Seretide Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Ventolin Normalized identity: VentolinView linked drug · Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention placebo Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Anti-IgE Monoclonal Antibody Treatment in Patients With Allergic Asthma.

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE3

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2018-05-09

PhasePHASE3

Conditions

Asthma, Allergicunresolved

Interventions

CMAB007DRUG

SymbicortDRUG · verified · RxNorm: Symbicort

SeretideDRUG

VentolinDRUG · verified · RxNorm: Ventolin

placeboDRUG

Sponsors & collaborators

Shanghai Biomabs Pharmaceutical Co., Ltd.lead sponsor

Mapped research locations

GuangzhouGuangdong, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03468790 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.